These findings are also in agreement with studies showing that PPARα null mice are deficient in FGF21 and that treating these mice with FGF21 improves hypertriglyceridemia and hypoketonemia (Lundåsen et al., 2007). Here, FGF21 is linked to hypertriglyceridemia.